The work of Australia’s Associate Professor Michael Lawless to obtain real-world data on the new Alcon AcrySof IQ Vivity presbyopia-correcting IOL will be presented at the 34th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting this weekend.
Lawless’ Vivity IOL data – in patients with previous refractive surgery – will be among 30 abstracts featuring Alcon ophthalmic products and equipment, at the meeting in Seoul 11-12 June.
Out of the 30 abstracts supported by Alcon at the meeting, 15 feature its presbyopia-correcting IOLs: the AcrySof IQ Vivity IOL and AcrySof IQ PanOptix IOL.
Lawless, who has previously said Vivity has the potential to replace monofocals and become his default lens, et al conducted a multicentre, ambispective registry study to present real-world data on the use Vivity in 23 patients with previous myopia-correcting corneal refractive surgery and six with previous hyperopia-correcting corneal refractive surgery.
Vivity is said to be a first-of-its-kind lens with Alcon’s non-diffractive X-WAVE technology that stretches and shifts light without splitting it. All patients have received bilateral DFT015/DFTX15-Toric implants and were evaluated at least tree months after surgery.
- Both patient groups had mean best-corrected distance visual acuity (BCDVA) of 20/20, along with distance-corrected intermediate visual acuity (DCIVA) of 20/25 and near visual acuity (DCNVA) of 20/32 – 20/40.
- Most patients had no halos, glare, or starbursts. No halos, glare or starbursts were reported in 91.3%, 87.0%, and 91.3% respectively in patients with previous myopia-correcting corneal refractive surgery; and 83.3%, 100%, and 100% respectively, in patients with previous hyperopia-correcting corneal refractive surgery.
- 82.6% of patients with post-myopic and all with post-hyperopic refractive surgery were satisfied with their sight.
Meanwhile, another abstract will show that use of PanOptix Trifocal IOL is safe and effective, and results in satisfactory vision across distances and spectacle independence.
A prospective study by J Chang et al includes patients from China who received bilateral AcrySof IQ PanOptix Trifocal IOL implants. In the US, this is the first and only FDA-approved trifocal lens that improves near, intermediate, and distance vision.
The study has assessed postoperative and mesopic visual acuity at all three distances, in addition to sensitivities, satisfaction, and spectacle independence.
- Mean binocular uncorrected visual acuity (VA) was 0.05±0.06 logMAR at distance, 0.06±0.10 logMAR at intermediate (60 cm), and 0.04±0.05 logMAR at near (40 cm) distances.
- Mean halo score was 2.4/5, glare was 0.2/5, and starburst was 1.4/5.
- The mean satisfaction score was 4.3 out of 5.
- All patients said that they were no longer dependent on their spectacles, and no IOL exchange was needed.
Finally, a post-market clinical study from Korea demonstrated good visual outcomes and high surgeon satisfaction with the Clareon AutonoMe IOL.
This prospective, multicentre, single-arm study by S Yang et al assesses real-world clinical outcomes, safety, and IOL delivery performance with the Clareon AutonoMe in the first year after the surgery. It includes 85 patients who have received 125 eye implants, of which patients with 92% (n=116) implants completed the one-year postoperative visit. At year one:
- 99.1% of eyes had monocular BCDVA of 0.2 logMAR or better.
- The mean monocular uncorrected distant visual acuity (UCDVA) for the first eye was 0.077 ± 0.1362 logMAR and 0.052 ± 0.1069 logMAR for the second eye.
- No tilt, decentration of the IOLs, and no surface haze were reported. Glistenings were grade 0.
- All surgeons reported that the incision site insertion was “very easy” or “easy” and that IOL delivery was “very controllable” or “controllable”.
“We are pleased to be a part of APACRS, one of the most anticipated ophthalmology conferences in the region. This conference is an excellent platform to showcase new findings on how Alcon’s cutting-edge ophthalmology innovations can transform patients’ lives” said Mr Chintan Desai, vice president of surgical for Alcon Asia Pacific.
“Being here also gives us the opportunity to interact with leading experts and eyecare professionals to discuss clinical challenges and how our breakthrough technologies can improve patient outcomes.”
More reading
An IOL to change the cataract surgery paradigm?
Alcon launches breakthrough Vivity IOL in Australia
Alcon announces APAC leadership reshuffle
